Biomissile, a biotech company developing fully human domain antibody (UDAB^TM) and multi-specific antibody (UDAB-M^TM) recently announced the successful completion of a ￥200M (CNY) Series B fundraising. Proceeds from the financing will be used to advance the company’s UDAB-M^TM based therapeutic pipeline, and further extend its scientific and technical leadership. Series B financing was led by Kequan Fund, along with continued support by existing investor, Fosun Health Capital.

The news in Chinese can be found here: https://mp.weixin.qq.com/s/NgoCiuKgXZiHC_Y-Y_EYTQ